Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Pharmacokinetics of Targeting with Liposomes

Volumen 19, Edición 3, 2002, 42 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i3.20
Get accessGet access

SINOPSIS

The optimization of drug disposition in the body leads to an increase in its therapeutic effect and to a decrease in adverse effects. Liposomes can serve as a potential drug carrier for achieving this. However, the behavior of a drug carrier system under in vivo conditions is complex. Therefore, a more complete understanding of the pharmacokinetics of liposomes themselves, as well as that of the encapsulated drug, is required. The optimization of the pharmacokinetics of liposomes can be performed by linking a pharmacodynamic model of the free drugs that are encapsulated into liposomes. Sensitivity analysis was applied to optimize the delivery system to maximize the antitumor effect of liposomal doxorubicin (DOX). Advanced technology for ligand-mediated selective targeting and intracellular targeting is also introduced for antitumor agents and for gene delivery systems.

CITADO POR
  1. Cui JingXia, Li ChunLei, Guo WenMin, Li YanHui, Wang CaiXia, Zhang Li, Zhang Lan, Hao YanLi, Wang YongLi, Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?, Journal of Controlled Release, 118, 2, 2007. Crossref

  2. Cai Lulu, Qiu Neng, Li Xia, Luo Kaili, Chen Xiang, Yang Li, He Gu, Wei Yuquan, Chen Lijuan, A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells, International Journal of Pharmaceutics, 408, 1-2, 2011. Crossref

  3. Kamiya Hiroyuki, Akita Hidetaka, Harashima Hideyoshi, Pharmacokinetic and pharmacodynamic considerations in gene therapy, Drug Discovery Today, 8, 21, 2003. Crossref

  4. Dosage Form Considerations in Preformulation, in Handbook of Preformulation, 2006. Crossref

  5. Good Clinical Practice, in Handbook of Bioequivalence Testing, 2014. Crossref

  6. Literature Alerts, Journal of Microencapsulation, 20, 5, 2003. Crossref

  7. Bao Ande, Goins Beth, Klipper Robert, Negrete George, Phillips William T., Direct 99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil) for Pharmacokinetic and Non-Invasive Imaging Studies, Journal of Pharmacology and Experimental Therapeutics, 308, 2, 2004. Crossref

  8. Xu Bei, Jin Quansheng, Zeng Jun, Yu Ting, Chen Yan, Li Shuangzhi, Gong Daoqiong, He Lili, Tan Xiaoyue, Yang Li, He Gu, Wu Jinhui, Song Xiangrong, Combined Tumor- and Neovascular-“Dual Targeting” Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis, ACS Applied Materials & Interfaces, 8, 39, 2016. Crossref

  9. Terada Takeshi, Mizobata Miki, Kawakami Shigeru, Yamashita Fumiyoshi, Hashida Mitsuru, Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes, Journal of Controlled Release, 119, 3, 2007. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain